Physician profile
Rafael E Callanta
NPI 1881935237
$5,103.32
in general payments reported to CMS, 2019-2025
15 companies · $4,000 in 2025
The $4,000 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $464 · 2022: $358 · 2023: $152 · 2024: $129 · 2025: $4,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,808 · Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,808.00 |
| Food and Beverage | $473.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,821.98 | 2025 | Rs-4i Plus With Intersperse, Rs-Fbg |
| Abbvie INC. | $302.44 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $254.63 | 2021-2025 | Xtampza, Belbuca |
| Forte Bio-Pharma LLC | $173.49 | 2021-2025 | Prolate, Tanlor, Nalocet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.47 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $76.63 | 2021-2023 | Ztlido |
| Lundbeck LLC | $69.12 | 2021-2023 | Vyepti |
| Biodelivery Sciences International, INC. | $61.01 | 2021 | |
| Amgen INC. | $49.57 | 2021-2022 | |
| Protega Pharmaceutials INC | $40.60 | 2024-2025 | Roxybond |
| Novartis Pharmaceuticals Corporation | $39.40 | 2021 | |
| Lilly USA, LLC | $26.98 | 2021 | |
| Ibsa Pharma INC. | $24.39 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Callanta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.